Publications by authors named "Sarah C Patterson"
Article Synopsis
- Most aggressive lymphomas are usually treated with combination chemotherapy, like the "CHOP" regimen, which is believed to be optimal when drugs work well together (synergy).
- Research on PTCL cell lines shows that the CHOP regimen often exhibits antagonistic interactions rather than synergy, leading to questions about how to improve treatment effectiveness.
- Surprisingly, concurrent administration of these drugs still leads to maximum tumor cell kill, and this can be explained using the linear-quadratic model from radiology, suggesting that even with negative interactions, the way drugs are given can result in better clinical outcomes.
Most advanced cancers are treated with drug combinations. Rational design aims to identify synergistic combinations, but existing synergy metrics apply to preclinical, not clinical data. Here we propose a model of drug additivity for progression-free survival (PFS) to assess whether clinical efficacies of approved drug combinations are additive or synergistic.
View Article and Find Full Text PDFMost aggressive lymphomas are treated with combination chemotherapy, commonly as multiple cycles of concurrent drug administration. Concurrent administration is in theory optimal when combination therapies have synergistic (more than additive) drug interactions. We investigated pharmacodynamic interactions in the standard 4-drug 'CHOP' regimen in Peripheral T-Cell Lymphoma (PTCL) cell lines, and found that CHOP consistently exhibits antagonism and not synergy.
View Article and Find Full Text PDF